Catalogue: Drug target reagents
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
List view / Grid view
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
Researchers have developed an artificial intelligence to identify the best potential antibody drug from groups of up to a few thousand.
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
14 April 2021 | By Fluidigm
Watch our free on-demand webinar to learn more about using Imaging Mass Cytometry™ (IMC™) to measure over 40 protein targets with subcellular resolution.
Using cryo-electron microscopy, researchers have shown that the Spike (S) protein on cells exposed to the AstraZeneca vaccine is highly similar to the SARS-CoV-2 S protein.
A model of the SARS-CoV-2 Spike protein surface has uncovered vulnerabilities that researchers say could inform the development of COVID-19 vaccines.
Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.
Children with multisystem inflammatory syndrome have a unique immunological profile revealed by systems-level analyses.
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
Within this ebook, find articles on how a lead bNAb candidate was identified to combat COVID-19 and why antibodies could present the answer to HIV treatment and vaccines.
31 March 2021 | By
The new AdvanceBio Sialic Acid profiling and quantitation kit from Agilent provides workflows for the robust and rapid preparation of samples for sialic acid analysis, generating reliable downstream LC-FLD and LC-MS data.
Don’t miss the latest product hub from Fluidic Analytics, detailing the Fluidity One-W Serum which enables comprehensive profiling of protein-protein interactions, such as the antibody response to SARS-CoV-2, based on affinity – a crucial characteristic of protein interactions that traditional tests cannot easily quantify.
A novel artificial intelligence (AI) technique called ProteinGAN has shown success at studying well known proteins to develop new ones.